Samsung Biologics Signs Letter of Intent for 457.1 Billion KRW Contract Manufacturing Agreement with AstraZeneca
[Asia Economy Reporter Hwang Yoon-joo] Samsung Biologics announced on the 12th that it has signed a letter of intent for a contract to manufacture biopharmaceuticals on consignment with AstraZeneca worth 457.1 billion KRW. This accounts for 29.15% of its recent sales revenue.
Hot Picks Today
![[Breaking] Samsung Electronics Management: "The Principle That Rewards Are Given Where There Are Results Has Been Upheld"](https://cwcontent.asiae.co.kr/asiaresize/93/2026052014513970767_1779256299.png)
[Breaking] Samsung Electronics Management: "The Principle That Rewards Are Given Where There Are Results Has Been Upheld"
- "It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![[Breaking] Samsung Electronics Labor and Management Officially Sign Tentative Agreement](https://cwcontent.asiae.co.kr/asiaresize/307/2026052022492353201A.jpg)
